InterCure Ltd.

About InterCure Ltd.

InterCure Ltd., operating as Canndoc, is a leading and profitable cannabis company outside North America, listed on NASDAQ and TASE under the ticker INCR. Through its subsidiary Canndoc, Israel's largest licensed cannabis producer, InterCure offers GMP-certified, pharmaceutical-grade medical cannabis products. The company utilizes a market-leading distribution network, international partnerships, and a high-margin vertically integrated 'seed-to-sale' model to dominate the fastest-growing cannabis market outside the US.

Products & Services

Medical Cannabis Products:Pharmaceutical-grade medical cannabis products certified under Good Manufacturing Practices (GMP), produced by Canndoc, Israel's largest licensed cannabis producer.

Specialties

Medical Cannabis Production Pharmaceutical-Grade Cannabis Vertically Integrated Seed-to-Sale Model Global Cannabis Market Distribution

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement and Debt Financing T: - FT: Private Placement and Debt Financing	A: 18200000 MR: - FA: NIS 66 million FAN: 18200000	D: 2024-12-20 FD: 2024-12-20	4 investors

Private Placement and Debt Financing Latest

2024-12-20

$18.2M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

InterCure Ltd. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised